Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01190644 · OUTCOME

Change From Baseline in Hemoglobin Subtype A2 Following a Single Dose of Sotatercept

Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Participants With Solid Tumors · Source last updated 2023-11-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
Percentage of hemoglobin subtype A2
Interval / dispersion
Full Range
Time frame
Baseline (Day 1, pre-dose) and Day 29

What was measured

Blood samples were collected at baseline (Day 1, pre-dose) and on Day 29, and hemoglobin electrophoresis used, to measure the change from baseline in hemoglobin subtype A2 following a single dose of sotatercept.

Analysis population: All participants who received at least one dose of study treatment and had data for Change from Baseline in Hemoglobin Subtype A2 Following a Single Dose of Sotatercept

Groups in this outcome

Sotatercept

Participants received a single 35 mg dose of sotatercept by subcutaneous (SC) injection on Day 1, Day 43, and Day 85.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Sotatercept1

Reported measurements

Source class 1
Values in Percentage of hemoglobin subtype A2 · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Sotatercept0.0Not reported0.00.0Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.0
        upper Limit
        0.0
        value
        0.0
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    units
    Participants
description
Blood samples were collected at baseline (Day 1, pre-dose) and on Day 29, and hemoglobin electrophoresis used, to measure the change from baseline in hemoglobin subtype A2 following a single dose of sotatercept.
dispersion Type
Full Range
groups
  1. description
    Participants received a single 35 mg dose of sotatercept by subcutaneous (SC) injection on Day 1, Day 43, and Day 85.
    id
    OG000
    title
    Sotatercept
param Type
MEAN
population Description
All participants who received at least one dose of study treatment and had data for Change from Baseline in Hemoglobin Subtype A2 Following a Single Dose of Sotatercept
reporting Status
POSTED
time Frame
Baseline (Day 1, pre-dose) and Day 29
title
Change From Baseline in Hemoglobin Subtype A2 Following a Single Dose of Sotatercept
type
SECONDARY
unit Of Measure
Percentage of hemoglobin subtype A2

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice